Figure 5.

Antiviral activity of caffeic acid against ILHV investigated under different treatment conditions. (A,D,G,J) Culture supernatants were harvested at the indicated times; ILHV production was measured in the presence of 125 µM dilution CA in cells infected with MOI 1 by plaque-forming assay. (B,C,E,F,H,I,K,L) Culture supernatants and cell total RNA were harvested at the indicated time points. ILHV production was measured in the presence of 125 µM dilution of CA in cells infected with MOI 1, using real-time RT-PCR. (A) Viral load in co-treated A549 cells. (B) Viral RNA copy number in co-treated A549 cells content. (C) Viral RNA copy number in supernatant co-treated A549 cells. (D) Viral load in co-treated Vero cells. (E) Viral RNA copy number in co-treated Vero cells content. (F) Viral RNA copy number in supernatant co-treated Vero cells. (G) Viral load in post-treated A549 cells. (H) Viral RNA copy number in post-treated A549 cells content. (I) Viral RNA copy number in supernatant post-treated A549 cells. (J) Viral load in post-treated Vero cells. (K) Viral RNA copy number in post-treated Vero cells content. (I) Viral RNA copy number in supernatant post-treated Vero cells. Degree of significance indicated on the figure as follows: * p < 0.05.